Bio Medicus
Developer of point-of-care molecular diagnostic technologies and assays. Core technical areas include asymmetric isothermal nucleic acid amplification, centrifugal microfluidic (lab-on-disc) platforms with on-disc droplet compartmentalization and sample pre-processing, and design and manufacture of instruments for real-time nucleic acid amplification with fluorescence detection. Product pipelines include multiplex infectious-disease panels, tuberculosis resistance marker detection, sexually transmitted infection and meningitis panels, gastrointestinal and respiratory pathogen panels, and somatic mutation assays for liquid biopsy. The company holds IVD manufacturing certification and GMP recognition and conducts collaborative R&D and licensing with clinical and industry partners.
Industries
Nr. of Employees
small (1-50)
Bio Medicus
서울 금천구 가산디지털1로 212 코오롱디지털타워애스턴 805호
Products
Centrifugal microfluidic disc platform
Disc-based diagnostic platform using centrifugal microfluidics and on-disc droplet generation to perform integrated sample handling, on-disc plasma separation and nucleic acid testing for rapid molecular diagnostics.
Real-time nucleic acid amplification instrument
Instrument for performing and monitoring real-time nucleic acid amplification with fluorescence readout for use with compatible molecular assay kits.
Molecular assay pipelines for infectious diseases and mutation detection
Pipelines of molecular assays covering respiratory viruses, gastrointestinal pathogens, sexually transmitted infections, meningitis pathogens, bacterial panels, tuberculosis resistance markers, and somatic mutation panels for liquid biopsy.
Centrifugal microfluidic disc platform
Disc-based diagnostic platform using centrifugal microfluidics and on-disc droplet generation to perform integrated sample handling, on-disc plasma separation and nucleic acid testing for rapid molecular diagnostics.
Real-time nucleic acid amplification instrument
Instrument for performing and monitoring real-time nucleic acid amplification with fluorescence readout for use with compatible molecular assay kits.
Molecular assay pipelines for infectious diseases and mutation detection
Pipelines of molecular assays covering respiratory viruses, gastrointestinal pathogens, sexually transmitted infections, meningitis pathogens, bacterial panels, tuberculosis resistance markers, and somatic mutation panels for liquid biopsy.
Services
Partnership-based research and development and licensing arrangements with pharmaceutical companies, biomarker developers, and clinical institutions.
Partnership-based research and development and licensing arrangements with pharmaceutical companies, biomarker developers, and clinical institutions.
Expertise Areas
- Point-of-care molecular diagnostics
- Isothermal amplification methods
- Centrifugal microfluidics and lab-on-disc engineering
- Droplet digital molecular assays
Key Technologies
- Asymmetric isothermal amplification
- Centrifugal microfluidics (lab-on-disc)
- On-disc plasma separation and nucleic acid extraction
- Centrifugal droplet generation
News & Updates
Company participated in a national biopharma and startup investment forum organized by an industry development group, presenting technology and engaging with potential investors and industry partners.
Press articles describing company plans to commercialize a field molecular diagnostic device lineup and reporting on fundraising and partnership efforts to support product launch and scale-up.
Obtained manufacturing certification for a real-time nucleic acid amplification device intended for in vitro diagnostics; device will serve as a platform for multiple reagent products.
Received Certificate of GMP for manufacturing and quality control compliance for in vitro diagnostic devices. Certificate issue date and PDF available.
Selected for a government-supported international joint R&D program to introduce and further develop overseas technologies, targeting development of point-of-care diagnostics for companion animal diseases.
Awarded a national SME technology innovation development grant to commercialize a point-of-care molecular diagnostic test for bacterial and viral meningitis with participation from hospital partners.
Company participated in a national biopharma and startup investment forum organized by an industry development group, presenting technology and engaging with potential investors and industry partners.
Press articles describing company plans to commercialize a field molecular diagnostic device lineup and reporting on fundraising and partnership efforts to support product launch and scale-up.
Obtained manufacturing certification for a real-time nucleic acid amplification device intended for in vitro diagnostics; device will serve as a platform for multiple reagent products.
Received Certificate of GMP for manufacturing and quality control compliance for in vitro diagnostic devices. Certificate issue date and PDF available.
Selected for a government-supported international joint R&D program to introduce and further develop overseas technologies, targeting development of point-of-care diagnostics for companion animal diseases.
Awarded a national SME technology innovation development grant to commercialize a point-of-care molecular diagnostic test for bacterial and viral meningitis with participation from hospital partners.